We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

This study is currently recruiting participants.
Verified November 2017 by Jazz Pharmaceuticals
Sponsor:
ClinicalTrials.gov Identifier:
NCT03037203
First Posted: January 31, 2017
Last Update Posted: November 7, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Jazz Pharmaceuticals
  Purpose
This study is a 4-week, multicenter, randomized, double-blind, placebo-controlled, ascending dose, 4-period crossover study designed to evaluate the safety, tolerability, efficacy, and PK of JZP-110 (75, 150, and 300 mg) in the treatment of excessive sleepiness in adult subjects with idiopathic PD.

Condition Intervention Phase
Excessive Sleepiness Parkinson Disease Drug: JZP-110 Other: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

Resource links provided by NLM:


Further study details as provided by Jazz Pharmaceuticals:

Primary Outcome Measures:
  • Safety as assessed by the incidence of treatment emergent adverse events up until the last visit at week 5 [ Time Frame: Weekly through week 5 ]

Secondary Outcome Measures:
  • Assess the effect of JZP110 on the Maintenance of Wakefulness Test (MWT) compared to baseline vs. placebo [ Time Frame: Weekly through week 4 ]
  • Assess the effect of JZP110 on the Epworth Sleepiness Scale (ESS) score compared to baseline vs. placebo [ Time Frame: Weekly through week 4] ]

Estimated Enrollment: 49
Study Start Date: January 2017
Estimated Study Completion Date: April 2018
Estimated Primary Completion Date: April 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A
JZP-110 and Placebo
Drug: JZP-110
75 mg, 150 mg, 300 mg
Other: Placebo
Experimental: Arm B
JZP-110 and Placebo
Drug: JZP-110
75 mg, 150 mg, 300 mg
Other: Placebo
Placebo Comparator: Arm C
Placebo
Other: Placebo

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of idiopathic PD according to the UK PDS Brain Bank Criteria.
  2. Hoehn and Yahr stage 1, 2, or 3.
  3. Baseline ESS score >10.
  4. Baseline mean sleep latency of ≤20 minutes on the MWT.

Exclusion Criteria:

  1. Diagnosis of other degenerative Parkinsonian syndromes (e.g., progressive supranuclear palsy, multiple system atrophy [MSA], or dementia with Lewy bodies [DLB]).
  2. Usual nightly time in bed of <6 hours, including the night before the Baseline visit.
  3. Prior or documented history of moderate or severe obstructive sleep apnea (OSA).
  4. Has evidence at screening of severe cognitive impairment or has cognitive impairment that in the opinion of the investigator would prevent completion of study procedures or the ability to provide informed consent.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03037203


Contacts
Contact: Jazz Pharmaceuticals 650-496-3777

Locations
United States, Arizona
Mayo Clinic Scottsdale Recruiting
Scottsdale, Arizona, United States, 85259
Principal Investigator: Shyamal Mehta         
United States, California
Southern California Institute For Respiratory Diseases, Inc. Recruiting
Los Angeles, California, United States, 90048
Principal Investigator: Roy Artal         
Pacific Research Network, Inc Recruiting
San Diego, California, United States, 92103
Principal Investigator: Stephen Thein         
United States, Florida
PAB Clinical Research Recruiting
Brandon, Florida, United States, 33511
Principal Investigator: Danial Lorch         
MD Clinical Recruiting
Hallandale Beach, Florida, United States, 33009
Principal Investigator: Beth Safirstein         
QPS MRA (Miami Research Associates) Recruiting
Miami, Florida, United States, 33143
Principal Investigator: Timothy Grant         
USF Health Byrd Institute Recruiting
Tampa, Florida, United States, 33613
Principal Investigator: Robert Hauser         
United States, Maryland
Center for Sleep & Wake Disorders Recruiting
Chevy Chase, Maryland, United States, 20815
Principal Investigator: Helene Emsellem         
United States, Michigan
Clinical Neurophysiology Services, P.C. Recruiting
Sterling Heights, Michigan, United States, 48314
Principal Investigator: Rahul Sangal         
United States, Missouri
St. Lukes Hospital Medical Center Recruiting
Chesterfield, Missouri, United States, 63017
Principal Investigator: Paula Schweitzer         
United States, New York
Strong Sleep Disorders Center Recruiting
Rochester, New York, United States, 14618
Principal Investigator: Michael Yurcheshen         
United States, Pennsylvania
Parkinson's Disease Research Unit - Thomas Jefferson University Recruiting
Philadelphia, Pennsylvania, United States, 19107
Principal Investigator: Jay Schneider         
United States, South Carolina
SleepMed of South Carolina Recruiting
Columbia, South Carolina, United States, 29201
Principal Investigator: Richard Bogan         
United States, Texas
Houston Neurology and Sleep Center Recruiting
Houston, Texas, United States, 77063
Principal Investigator: Todd Swick         
United States, Washington
Evergreen Hospital Medical Center Recruiting
Kirkland, Washington, United States, 98034
Principal Investigator: Alida Griffith         
Premier Clinical Research - Sherman Active, not recruiting
Spokane, Washington, United States, 99202
Sponsors and Collaborators
Jazz Pharmaceuticals
Investigators
Study Director: Millie Gottwald, PharmD Jazz Pharmaceuticals
  More Information

Responsible Party: Jazz Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03037203     History of Changes
Other Study ID Numbers: JZP166-201
First Submitted: January 23, 2017
First Posted: January 31, 2017
Last Update Posted: November 7, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Parkinson Disease
Disorders of Excessive Somnolence
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Mental Disorders